PET Scan Tracer Detects Brain Inflammation in Multiple Sclerosis
Tests a new radioactive tracer scan for brain inflammation in healthy adults and multiple sclerosis.
Plain-language title generated from the registry record
Registry title: This Study Involves a Positron Emission Tomography (PET) Scan Using a New Investigational Radioactive Tracer, [18F]-FZTA, to Detect Inflammation in the Brain. The Tracer Will be Tested in Healthy Younger Adults and Individuals With Multiple Sclerosis.
Key facts
- Where
- St Louis, United StatesSee the site
Where in United States
- Washington University in St. LouisSt Louis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Washington University School of Medicine
- Trial code
- NCT07115017
- Record updated
- 4 August 2026
- Original description
This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, [18F]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.Read full original descriptionShow less
Investigation of Inflammation Using [18F]FZTA
This study involves a Positron Emission Tomography (PET) scan using a new investigational radioactive tracer, [18F]-FZTA, to detect inflammation in the brain. The tracer will be tested in healthy younger adults and individuals with Multiple Sclerosis.
Inclusion: Male or female, any race; Age ≥ 18 years; Capable of providing written informed consent for volunteering to undergo research procedures; Healthy volunteer or volunteer with a diagnosis of MS established using the revised McDonald criteria (2017).
Exclusion: Currently undergoing radiation therapy; Current or recent (within 12 months prior to screening) participation in research studies involving radioactive agents such that the total research-related radiation dose to the participant in any given year would exceed the limits set forth in the U.S. Code of Federal Regulations (CFR) Title 21 Section 361.1; Hypersensitivity to [18F]FZTA or any of its excipients; Any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection of the data (e.g., renal or liver failure, advanced cancer); Participants who in the last 6 months experienced any of the following cardiovascular conditions or findings in the screening electrocardiogram (ECG): clinically significant cardiac arrhythmias including atrial fibrillation with rapid ventricular response, myocardial infarction, high-grade heart block (type 2 or greater), unstable angina, stroke, transient ischemic attack or decompensated heart failure requiring hospitalization or Class III/IV heart failure; Contraindications to PET, CT, or MRI (e.g., certain incompatible electronic medical devices, inability to lie still for extended periods) that make it potentially unsafe for the individual to participate; Severe claustrophobia; Women who are currently pregnant or breastfeeding.